IgY-technology for sustainable development: A policy brief

Science-policy brief accepted for the Eighth annual Multi-Stakeholder Forum on Science, Technology and Innovation for the SDGs (STI Forum).

Forum website: https://sdgs.un.org/tfm/STIForum2023

Abstract:
IgY-technology (the production and extraction of specific IgY antibodies from egg yolk) is an innovative method to produce antibodies for therapy and prophylaxis. Many research groups have demonstrated that IgY is active against several pathogens or conditions, a fact that may support the design of novel, safe and effective health products. In fact, IgY-technology not only targets SDG 3 (Good health and well-being) but also SDG 9 (Industry, innovation, and infrastructure) and 17 (Partnerships for the goals) which offers an opportunity for developing countries to tackle current and future health challenges. Therefore, the aim of this policy brief is to provide an outline of empirical facts as well as a prospective work related to IgY-technology and the oral administration of egg yolk antibodies as prophylaxis and therapy in a wide range of infectious and non-communicable diseases.